This table lists all the major pharma collaborations, acquisitions and mergers agreed during May 2014.
For an indepth analysis of these deals, read ‘Pharma deals during May 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Merck & Co OTC Business / Bayer | Asset / product acquisition | Consumer care business incl. Claritin, Afrin and Coppertone brands | 14,200 |
| CFR Pharmaceuticals / Abbott | Company acquisition | Chile-based branded generic company with Latin America (2013 sales $768m) | 3,330 |
| Bayer / Merck & Co | Co-development and co-commercialisation | Soluble guanylate cyclase modulators for cardiovascular disease | 2,100 |
| Valeant / Nestle | Asset / product acquisition | Injectable cosmetic fillers for facial wrinkles including Dysport | 1,400 |
| Ophthotech / Novartis | Commercialisation1 and co-development licence | Fovista (start p3) for treatment of wet age-related macular degeneration | 1,030 |
| Chelsea / Lundbeck | Company acquisition | US company with treatments for rare neurologic diseases | 658 |
| Avalanche / Regeneron | Development and commercialisation licence | Gene therapy products for ophthalmologic disease | 653 |
| Merck & Co / Santen | Asset / product acquisition2 | Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m | 600+ |
| MacroGenics / Takeda | Option to license end p1a to develop and commercialise | MGD010, a preclinical bispecific antibody for treatment of auto-immune disease | 502 |
| VersaPharm / Akorn | Company acquisition | US generic company selling dermatology products with $100m sales | 440 |
| Bayer Interventional Device Business / Boston Scientific | Asset / product acquisition | Devices for coronary and peripheral vascular disease (2013 sales $120m) | 415 |
| CytomX / BMS | Development and commercialisation licence | Selective monoclonal antibodies (“Probodies”) for up to 4 oncology targets | 348 |
| Bedford Labs (Boehringer Ingelheim) / Hikma | Asset / product acquisition | US generic injectable manufacturer and products (2013 sales $19m) | 300 |
| GSK product / Pernix | Asset / product acquisition3 | Marketed sumatriptan/naproxen combination. 2013 sales $79m | 267 |
| Lumena / Shire | Company acquisition | US company with late stage compounds for treatment of rare GI / hepatic diseases | 260+ |
| Xenoport / Reckitt Benckiser | Development and commercialisation licence | Arbaclofen placarbil end pIIa for alcohol use disorders | 145 |
| Neurotez / GCA Therapeutics | Development and commercialisation licence4 | Leptin derivatives for treatment of cognitive disorders | 103 |
| Fibrotech / Shire | Company acquisition | Australian company with pIb product for rare fibrotic kidney disease | 75+ |
| Ligand / Omthera (AstraZeneca) | Research, development and commercialisation licence | Omthera’s prodrug delivery platform for omega-3 fatty acids for dyslipidaemia | 45 |
| Viking / Ligand | Licence to develop. Ligand provides $2.5m loan | Five development small molecule programmes. Lead product pIIb type 2 diabetes | N/D |
| AntiOp / Reckitt Benckiser | Supply and marketing agreement | Intranasal naloxone for opioid abuse in late clinical development | N/D |
All deals are worldwide unless otherwise noted.
1 – Ex-US
2 – Japan and key markets in Europe and Asia Pacific
3 – US
4 – China